Christine Hunter – Hyperkinetic Movement Disorders

Access Program Information

Although the results of studies looking at tetrabenazine have shown its effectiveness in the
management of hyperkinetic(too much) movement disorders, it has not been made available in
the U.S. The drug must be obtained from Cambridge Laboratories, the distributor, using an
individual IND (#16,161). The cost of the drug is passed on to the patient. The purpose of
the protocol is to provide an efficacious drug, with few side effects, in an attempt to get
rid of a variety of incapacitating dyskinesias (abnormal movements).